Razoxane 是拓扑异构酶 II的有效抑制剂，具有抗血管生成的作用，在肾细胞癌中具有研究价值。

Razoxane is used as an antimitotic agent with immunosuppressive properties.

This tumor model is characterized by osteoid formation and spontaneous metastasization to lungs, kidneys and lymph nodes. Razoxane given intraperitoneally (i.p.) from 2 days before to 14 days after tumor transplantation (30 mg/kg or 10 mg/kg per day) resulted in a dose-dependent prolongation of median survival time (83 or 48 days respectively, versus 38 days for the control group), but showed no influence on the growth of the primary tumor. Early treatment with razoxane (30 mg/kg i.p. from day -2 to +14) showed a greater inhibition of pulmonary metastases than later treatment (30 mg/kg i.p. from day +14 to +28 after transplantation). Whereas 59.9 per cent of the total sectional area of the lungs in the control animals was covered by osteosarcoma metastases, only 3.4 per cent and 26.1 per cent respectively was affected in the early and late razoxane treatment groups. Toxic side-effects of these treatment schedules were reversible diffuse alopecia, but no retardation of body weight gain[2].

21416-67-1

C11H16N4O4

268.27

DMSO:60 mg/ml (223.66 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years